目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET SIZE ESTIMATION
2.2.2 SEGMENTAL MARKET ASSESSMENT
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
3.3 DISRUPTIVE TRENDS SHAPING MARKET

4 PREMIUM INSIGHTS
4.1 SINGLE-CELL SEQUENCING MARKET SNAPSHOT
4.2 NORTH AMERICA: SINGLE-CELL SEQUENCING MARKET, BY OFFERING & COUNTRY (2024)
4.3 SINGLE-CELL SEQUENCING MARKET FOR BASIC & TRANSLATION RESEARCH APPLICATIONS, BY TYPE (2024)
4.4 SINGLE-CELL SEQUENCING PRODUCTS MARKET, BY END USER (2024)
4.5 SINGLE-CELL SEQUENCING SERVICES MARKET, BY END USER (2024)
4.6 SINGLE-CELL SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in single-cell sequencing technologies
5.2.1.2 Growing focus on precision medicine and biomarker discovery
5.2.1.3 Integration of AI & ML in data analysis
5.2.1.4 Advantages over conventional bulk sequencing
5.2.2 RESTRAINTS
5.2.2.1 High cost of single-cell sequencing products & services
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of SBX technology
5.2.3.2 Integration of multi-omics technologies
5.2.3.3 Growth potential of emerging economies
5.2.4 CHALLENGES
5.2.4.1 Complexities associated with high-dimensional single-cell data
5.2.4.2 Biological variability and cell heterogeneity
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT IN SINGLE-CELL SEQUENCING MARKET
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Microfluidics partitioning
5.6.1.2 NGS
5.6.1.3 PCR
5.6.1.4 Flow cytometry
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Magnetic-activated Cell Sorting (MACS)
5.6.2.2 Tissue dissociation systems
5.6.2.3 Combinatorial indexing
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Bulk RNA-seq
5.6.3.2 In situ hybridization (ISH)
5.7 PATENT ANALYSIS
5.7.1 PATENT METHODOLOGY
5.7.2 PATENTS APPLIED & GRANTED, 2014-2024
5.8 TRADE ANALYSIS
5.8.1 IMPORT DATA (HS CODE 9027)
5.8.2 EXPORT DATA (HS CODE 9027)
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 TARIFF & REGULATORY LANDSCAPE
5.10.1 TARIFF DATA (HS CODE 9027)
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.3 REGULATORY FRAMEWORK
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022 -2024
5.11.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
5.13.3 BUYING CRITERIA
5.14 CUSTOMER LANDSCAPE
5.14.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
5.14.2 UNMET NEEDS & WHITE SPACES
5.15 INVESTMENT & FUNDING ACTIVITIES
5.16 IMPACT OF AI/GENERATIVE AI ON SINGLE-CELL SEQUENCING MARKET
5.16.1 AI-USE CASES
5.16.2 KEY COMPANIES IMPLEMENTING AI
5.16.3 FUTURE OF AI IN SINGLE-CELL SEQUENCING
5.17 TRUMP TARIFF IMPACT ON SINGLE-CELL SEQUENCING MARKET
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 KEY IMPACT ON VARIOUS REGIONS
5.17.4.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.4.4 Rest of the World
5.17.5 END-USE INDUSTRY IMPACT
5.17.5.1 Pharmaceutical & biotech companies
5.17.5.2 CROs
5.17.5.3 Academic & research institutes
5.17.5.4 Hospitals & clinical laboratories

6 SINGLE-CELL SEQUENCING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 RECURRING DEMAND FOR CONSUMABLES TO DRIVE MARKET
6.3 SERVICES
6.3.1 HIGH RELIANCE ON SERVICE PROVIDERS FOR SEQUENCING ACTIVITIES TO PROPEL MARKET

7 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 PRE-SEQUENCING REAGENTS & KITS
7.2.1.1 Ongoing product launches & upgrades to fuel uptake
7.2.2 SEQUENCING REAGENTS & KITS
7.2.2.1 Ability to provide high-throughput and high-fidelity nucleotide reading to boost demand
7.3 INSTRUMENTS
7.3.1 PRE-SEQUENCING INSTRUMENTS
7.3.1.1 Microfluidic instruments
7.3.1.1.1 Increasing demand for reproducible & low-input single-cell workflows to fuel uptake
7.3.1.2 Cell sorters
7.3.1.2.1 Provision of high-precision isolation of viable cells to boost demand
7.3.1.3 PCR instruments
7.3.1.3.1 High sensitivity & reproducibility features to fuel uptake
7.3.1.4 LCM instruments
7.3.1.4.1 Increasing use across applications requiring spatial resolution to support demand
7.3.1.5 Other pre-sequencing instruments
7.3.2 SEQUENCING PLATFORMS
7.3.2.1 Rising adoption across research applications to drive market
7.4 SOFTWARE
7.4.1 SOFTWARE TOOLS
7.4.1.1 Rising demand for accurate & scalable processing of sequencing data to support market growth
7.4.2 DATA STORAGE & MANAGEMENT SOFTWARE
7.4.2.1 Secure handling, archival, and retrieval of large volumes of data to support market growth

8 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY WORKFLOW
8.1 INTRODUCTION
8.2 PRE-SEQUENCING WORKFLOW
8.2.1 ABILITY TO ENABLE HIGH-THROUGHPUT WORKFLOW IN CLINICAL & RESEARCH SETTINGS TO DRIVE MARKET
8.3 SEQUENCING WORKFLOW
8.3.1 DEMAND FOR MULTI-OMIC SEQUENCING PLATFORMS IN TRANSLATIONAL RESEARCH & ONCOLOGY TO PROPEL MARKET
8.4 DATA ANALYSIS & INTERPRETATION WORKFLOW
8.4.1 COMPLEXITY OF SINGLE-CELL DATASETS TO FUEL MARKET

9 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY END USER
9.1 INTRODUCTION
9.2 ACADEMIC & RESEARCH INSTITUTES
9.2.1 RISING FOCUS ON LIFE SCIENCES RESEARCH SUPPORTED BY FAVORABLE GRANTS & FUNDS TO DRIVE MARKET
9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
9.4 HOSPITALS & CLINICAL LABORATORIES
9.4.1 RISING INTEGRATION OF ADVANCED SEQUENCING TECHNOLOGIES INTO CLINICAL WORKFLOWS TO BOOST DEMAND
9.5 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.5.1 INCREASING RELIANCE ON OUTSOURCING R&D ACTIVITIES TO SUPPORT MARKET GROWTH

10 SINGLE-CELL SEQUENCING SERVICES MARKET, BY TYPE
10.1 INTRODUCTION
10.2 PRE-SEQUENCING SERVICES
10.2.1 SAMPLE PREPARATION, SINGLE-CELL ISOLATION, AND ENRICHMENT SERVICES
10.2.1.1 Rising demand for high-resolution cell profiling services to fuel market
10.2.2 LIBRARY PREPARATION SERVICES
10.2.2.1 Adoption of single-cell applications to fuel market
10.3 SEQUENCING SERVICES
10.3.1 INCREASING DEMAND FOR SCALABLE & APPLICATION-SPECIFIC SEQUENCING OUTPUTS TO DRIVE MARKET
10.4 DATA ANALYSIS & BIOINFORMATICS SERVICES
10.4.1 INCREASING FOCUS ON CREATION OF END-TO-END ANALYSIS PIPELINES TO SUPPORT MARKET GROWTH

11 SINGLE-CELL SEQUENCING SERVICES MARKET, BY END USER
11.1 INTRODUCTION
11.2 ACADEMIC & RESEARCH INSTITUTES
11.2.1 EXECUTION OF COMPLEX & LARGE-SCALE CELLULAR STUDIES TO DRIVE MARKET
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3.1 INTEGRATION OF HIGH-THROUGHPUT SINGLE-CELL PLATFORMS IN DRUG DISCOVERY ACTIVITIES TO PROPEL MARKET
11.4 HOSPITALS & CLINICAL LABORATORIES
11.4.1 INCREASING USE ACROSS ONCOLOGY DIAGNOSTICS TO SUPPORT MARKET GROWTH

12 SINGLE-CELL SEQUENCING MARKET, BY SEQUENCING TYPE
12.1 INTRODUCTION
12.2 SINGLE-CELL TRANSCRIPTOME SEQUENCING (SCRNA-SEQ)
12.2.1 WIDE APPLICATIONS FOR GENE EXPRESSION STUDIES TO DRIVE MARKET
12.3 SINGLE-CELL GENOME SEQUENCING (SCDNA-SEQ)
12.3.1 ANALYSIS OF GENOMIC VARIATIONS WITH COMPLEX ADVANCEMENTS TO FUEL MARKET
12.4 SINGLE-CELL ATAC SEQUENCING (SCATAC-SEQ)
12.4.1 IDENTIFICATION OF OPEN DNA REGIONS TO SUPPORT MARKET GROWTH
12.5 OTHER SINGLE-CELL SEQUENCING TYPES

13 SINGLE-CELL SEQUENCING MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 RESEARCH APPLICATIONS
13.2.1 BASIC & TRANSLATION RESEARCH
13.2.1.1 Cancer research
13.2.1.1.1 Growing demand for oncology therapeutics to drive market
13.2.1.2 Stem cell & developmental biology
13.2.1.2.1 Mapping stem cell heterogeneity and lineage dynamics with high precision to boost demand
13.2.1.3 Neurology & brain research
13.2.1.3.1 Growing focus on psychiatric & neurodevelopmental disorder research to fuel market
13.2.1.4 Microbiology & infectious diseases
13.2.1.4.1 Precise profiling of immune responses & pathogen behavior to boost demand
13.2.1.5 Organ development & regenerative medicine
13.2.1.5.1 Growing focus on precision medicine to fuel uptake
13.2.2 DRUG DISCOVERY & DEVELOPMENT
13.2.2.1 Improved target validation and patient stratification using single-cell data to drive market
13.3 DIAGNOSTIC & CLINICAL APPLICATIONS
13.3.1 RISING UPTAKE IN MOLECULAR DIAGNOSTICS & PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH

14 SINGLE-CELL SEQUENCING MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Increasing R&D investments & funding to drive market
14.2.3 CANADA
14.2.3.1 High prevalence of hemophilia to propel market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Increasing awareness of advanced cell therapies to drive market
14.3.3 UK
14.3.3.1 Rising adoption of single-cell analysis products to boost demand
14.3.4 FRANCE
14.3.4.1 Favorable government funding investments for genomics to fuel market
14.3.5 ITALY
14.3.5.1 Growing focus on cell biology research to fuel uptake
14.3.6 SPAIN
14.3.6.1 Increasing number of biotechnology companies to drive market
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 CHINA
14.4.2.1 Increasing incidence of infectious diseases to drive market
14.4.3 JAPAN
14.4.3.1 Growing demand for personalized medicine to drive market
14.4.4 INDIA
14.4.4.1 Expansion of activities in cell biology and biotech sectors to drive market
14.4.5 SOUTH KOREA
14.4.5.1 Increasing number of strategic alliances to boost market
14.4.6 AUSTRALIA
14.4.6.1 Rising establishment of life science companies to boost demand
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Focus on advancements in manufacturing infrastructure for biopharmaceuticals to propel market
14.5.3 MEXICO
14.5.3.1 Favorable government support for advanced sequencing technologies to drive market
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
14.6.2 GCC COUNTRIES
14.6.2.1 Kingdom of Saudi Arabia (KSA)
14.6.2.1.1 Increasing healthcare expenditure to drive market
14.6.2.2 United Arab Emirates
14.6.2.2.1 Improvements in medical sector to fuel uptake
14.6.2.3 Other GCC Countries
14.6.3 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 RISING FOCUS ON DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
14.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
15.3 REVENUE ANALYSIS, 2022-2024
15.4 MARKET SHARE ANALYSIS, 2024
15.5 COMPANY EVALUATION MATRIX: KEY PRODUCT PROVIDERS, 2024
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product type footprint
15.5.5.4 Workflow footprint
15.5.5.5 Application footprint
15.6 COMPANY EVALUATION MATRIX: KEY SERVICE PROVIDERS, 2024
15.6.1 STARS
15.6.2 EMERGING LEADERS
15.6.3 PERVASIVE PLAYERS
15.6.4 PARTICIPANTS
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.6.5.1 Company footprint
15.6.5.2 Region footprint
15.6.5.3 Service footprint
15.6.5.4 Application footprint
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
15.7.1 PROGRESSIVE COMPANIES
15.7.2 RESPONSIVE COMPANIES
15.7.3 DYNAMIC COMPANIES
15.7.4 STARTING BLOCKS
15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
15.7.5.1 Detailed list of key startups/SMEs
15.7.5.2 Competitive benchmarking of key startups/SMEs
15.8 COMPANY VALUATION & FINANCIAL METRICS
15.8.1 FINANCIAL METRICS
15.8.2 COMPANY VALUATION
15.9 BRAND/PRODUCT COMPARISON
15.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
15.10 COMPETITIVE SCENARIO
15.10.1 PRODUCT & SERVICE LAUNCHES
15.10.2 DEALS

16 COMPANY PROFILES
16.1 INTRODUCTION
16.2 KEY PRODUCT PROVIDERS
16.2.1 BECTON, DICKINSON AND COMPANY (BD)
16.2.1.1 Business overview
16.2.1.2 Products offered
16.2.1.3 Recent developments
16.2.1.3.1 Product launches
16.2.1.3.2 Deals
16.2.1.4 MnM view
16.2.1.4.1 Key strengths
16.2.1.4.2 Strategic choices
16.2.1.4.3 Weaknesses & competitive threats
16.2.2 THERMO FISHER SCIENTIFIC INC.
16.2.2.1 Business overview
16.2.2.2 Products offered
16.2.2.3 Recent developments
16.2.2.3.1 Product launches
16.2.2.4 MnM view
16.2.2.4.1 Key strengths
16.2.2.4.2 Strategic choices
16.2.2.4.3 Weaknesses & competitive threats
16.2.3 DANAHER CORPORATION
16.2.3.1 Business overview
16.2.3.2 Products offered
16.2.3.3 Recent developments
16.2.3.3.1 Product launches
16.2.3.3.2 Deals
16.2.3.4 MnM view
16.2.3.4.1 Key strengths
16.2.3.4.2 Strategic choices
16.2.3.4.3 Weaknesses & competitive threats
16.2.4 10X GENOMICS
16.2.4.1 Business overview
16.2.4.2 Products offered
16.2.4.3 Recent developments
16.2.4.3.1 Product launches
16.2.4.3.2 Deals
16.2.4.4 MnM view
16.2.4.4.1 Key strengths
16.2.4.4.2 Strategic choices
16.2.4.4.3 Weaknesses & competitive threats
16.2.5 ILLUMINA, INC.
16.2.5.1 Business overview
16.2.5.2 Products offered
16.2.5.3 Recent developments
16.2.5.3.1 Product launches
16.2.5.3.2 Deals
16.2.5.4 MnM view
16.2.5.4.1 Key strengths
16.2.5.4.2 Strategic choices
16.2.5.4.3 Weaknesses & competitive threats
16.2.6 MERCK KGAA
16.2.6.1 Business overview
16.2.6.2 Products offered
16.2.7 QIAGEN N.V.
16.2.7.1 Business overview
16.2.7.2 Products offered
16.2.8 BIO-RAD LABORATORIES, INC.
16.2.8.1 Business overview
16.2.8.2 Products offered
16.2.8.3 Recent developments
16.2.8.3.1 Product launches
16.2.9 TECAN TRADING AG
16.2.9.1 Business overview
16.2.9.2 Products offered
16.2.9.3 Recent developments
16.2.9.3.1 Product launches
16.2.9.3.2 Deals
16.2.10 CYTEK BIOSCIENCES
16.2.10.1 Business overview
16.2.10.2 Products offered
16.2.10.3 Recent developments
16.2.10.3.1 Product launches
16.2.10.3.2 Deals
16.2.10.3.3 Expansions
16.2.11 TAKARA BIO INC.
16.2.11.1 Business overview
16.2.11.2 Products offered
16.2.11.3 Recent developments
16.2.11.3.1 Product launches
16.2.11.3.2 Deals
16.2.12 BIO-TECHNE
16.2.12.1 Business overview
16.2.12.2 Products offered
16.2.12.3 Recent developments
16.2.12.3.1 Deals
16.2.13 PACBIO
16.2.13.1 Business overview
16.2.13.2 Products offered
16.2.13.3 Recent developments
16.2.13.3.1 Product launches
16.3 KEY SERVICE PROVIDERS
16.3.1 AZENTA US INC.
16.3.1.1 Business overview
16.3.1.2 Services offered
16.3.2 NOVOGENE CO., LTD.
16.3.2.1 Business overview
16.3.2.2 Services Offered
16.3.2.3 Recent developments
16.3.2.3.1 Service launches
16.3.2.3.2 Expansions
16.3.3 IQVIA INC.
16.3.3.1 Business overview
16.3.3.2 Services offered
16.3.4 ALMAC GROUP
16.3.4.1 Business overview
16.3.4.2 Services offered
16.3.5 CEGAT GMBH
16.3.5.1 Business overview
16.3.5.2 Services offered
16.3.6 ACTIVE MOTIF
16.3.6.1 Business overview
16.3.6.2 Services offered
16.4 OTHER PRODUCT PROVIDERS
16.4.1 SINGLERON BIOTECHNOLOGIES
16.4.2 CELL MICROSYSTEMS
16.4.3 NANOCELLECT BIOMEDICAL
16.4.4 OXFORD NANOPORE TECHNOLOGIES PLC.
16.4.5 REVVITY
16.4.6 PARSE BIOSCIENCES
16.4.7 ULTIMA GENOMICS
16.4.8 MISSION BIO
16.5 OTHER SERVICE PROVIDERS
16.5.1 SINGLE CELL DISCOVERIES BV
16.5.2 ADMERA HEALTH
16.5.3 BGI
16.5.4 SIGNIOSBIO
16.5.5 MACROGEN CO., LTD.
16.5.6 LEXOGEN GMBH
16.5.7 DISCOVERY LIFE SCIENCES
16.5.8 CELLCARTA
16.5.9 SINGULOMICS CORPORATION
16.5.10 SEQMATIC LLC.

17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS